Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease

Randomized Study ◽

Faculty Opinions recommendation of Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725355266.793521191 ◽

2016 ◽

Author(s):

Jai Radhakrishnan

Keyword(s):

Heart Failure ◽

Chronic Kidney Disease ◽

Chronic Heart Failure ◽

Kidney Disease ◽

Receptor Antagonist ◽

Randomized Study ◽

Faculty Opinions recommendation of Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718013671.793497213 ◽

2014 ◽

Author(s):

Anne Dorrance

Keyword(s):

Heart Failure ◽

Chronic Kidney Disease ◽

Chronic Heart Failure ◽

Kidney Disease ◽

The Novel ◽

Double Blind Trial ◽

Double Blind ◽

Moderate Chronic Kidney Disease

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

European Heart Journal ◽

10.1093/eurheartj/eht187 ◽

2013 ◽

Vol 34 (31) ◽

pp. 2453-2463 ◽

Cited By ~ 212

Author(s):

Bertram Pitt ◽

Lars Kober ◽

Piotr Ponikowski ◽

Mihai Gheorghiade ◽

Gerasimos Filippatos ◽

...

Keyword(s):

Heart Failure ◽

Chronic Kidney Disease ◽

Chronic Heart Failure ◽

Kidney Disease ◽

The Novel ◽

Double Blind Trial ◽

Double Blind ◽

Moderate Chronic Kidney Disease

Effects of mineralocorticoid receptor antagonist spironolactone on cardiac sympathetic nerve activity and prognosis in patients with chronic heart failure

International Journal of Cardiology ◽

10.1016/j.ijcard.2011.12.080 ◽

2013 ◽

Vol 167 (1) ◽

pp. 244-249 ◽

Cited By ~ 15

Author(s):

Shu Kasama ◽

Takuji Toyama ◽

Hiroyuki Sumino ◽

Hisao Kumakura ◽

Yoshiaki Takayama ◽

...

Keyword(s):

Heart Failure ◽

Chronic Heart Failure ◽

Receptor Antagonist ◽

Sympathetic Nerve ◽

Sympathetic Nerve Activity ◽

Cardiac Sympathetic Nerve ◽

Nerve Activity ◽

Cardiac Sympathetic Nerve Activity

The importance of a higher dose of a mineralocorticoid receptor antagonist in reducing risk of reccurent hospitalization in a patient with advanced chronic heart failure - A case report

Cor et Vasa ◽

10.1016/j.crvasa.2017.08.004 ◽

2018 ◽

Vol 60 (5) ◽

pp. e527-e530 ◽

Cited By ~ 1

Author(s):

Ghada Mairgani ◽

Václav Mála ◽

Filip Málek

Keyword(s):

Heart Failure ◽

Case Report ◽

Chronic Heart Failure ◽

Receptor Antagonist ◽

ELEVATED GALECTIN-3 DOES NOT PREDICT BENEFIT FROM MINERALOCORTICOID RECEPTOR ANTAGONIST USE IN PATIENTS WITH CHRONIC HEART FAILURE DUE TO LEFT VENTRICULAR SYSTOLIC DYSFUNCTION

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(15)60970-6 ◽

2015 ◽

Vol 65 (10) ◽

pp. A970

Author(s):

Parul U. Gandhi ◽

Shweta Motiwala ◽

Arianna Belcher ◽

Hanna Gaggin ◽

Rory Weiner ◽

...

Keyword(s):

Heart Failure ◽

Chronic Heart Failure ◽

Receptor Antagonist ◽

Left Ventricular Systolic Dysfunction ◽

Systolic Dysfunction ◽

Left Ventricular ◽

Ventricular Systolic Dysfunction ◽

Galectin 3

Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease

Expert Opinion on Investigational Drugs ◽

10.1517/13543784.2015.1059819 ◽

2015 ◽

Vol 24 (8) ◽

pp. 1123-1135 ◽

Cited By ~ 32

Author(s):

Licette CY Liu ◽

Elise Schutte ◽

Ron T Gansevoort ◽

Peter van der Meer ◽

Adriaan A Voors

Keyword(s):

Heart Failure ◽

Kidney Disease ◽

Receptor Antagonist ◽

Diabetic Kidney Disease ◽

Third Generation ◽

Diabetic Kidney

Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction

American Heart Journal ◽

10.1016/j.ahj.2014.12.012 ◽

2015 ◽

Vol 169 (3) ◽

pp. 404-411.e3 ◽

Cited By ~ 22

Author(s):

Parul U. Gandhi ◽

Shweta R. Motiwala ◽

Arianna M. Belcher ◽

Hanna K. Gaggin ◽

Rory B. Weiner ◽

...

Keyword(s):

Heart Failure ◽

Chronic Heart Failure ◽

Receptor Antagonist ◽

Left Ventricular Systolic Dysfunction ◽

Systolic Dysfunction ◽

Left Ventricular ◽

Ventricular Systolic Dysfunction ◽

Galectin 3

Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury–Mediated Chronic Kidney Disease

Hypertension ◽

10.1161/hypertensionaha.116.08526 ◽

2017 ◽

Vol 69 (5) ◽

pp. 870-878 ◽

Cited By ~ 33

Author(s):

Lionel Lattenist ◽

Sebastian M. Lechner ◽

Smail Messaoudi ◽

Alan Le Mercier ◽

Soumaya El Moghrabi ◽

...

Keyword(s):

Chronic Kidney Disease ◽

Acute Kidney Injury ◽

Kidney Disease ◽

Receptor Antagonist ◽

Kidney Injury ◽

O116 Does aspirin interfere with the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in systolic chronic heart failure?: Analysis of the EMPHASIS-HF study

Global Heart ◽

10.1016/j.gheart.2014.03.1327 ◽

2014 ◽

Vol 9 (1) ◽

pp. e31

Author(s):

Henry Krum ◽

Bertram Pitt ◽

John McMurray ◽

Karl Swedberg ◽

Dirk van Veldhuisen ◽

...

Keyword(s):

Heart Failure ◽

Chronic Heart Failure ◽

Failure Analysis ◽

Receptor Antagonist ◽

Clinical Benefits